Imugene (IMU) Collaboration summary

Opening remarks and agenda

• The session began with a 10-minute presentation followed by a Q&A segment for participants to submit questions via Zoom.

• Announced a strategic collaboration to evaluate a novel combination therapy for refractory solid tumors.

• The partnership was jointly released by both companies' CEOs and authorized by their leadership.

Objectives of the partnership

• The collaboration aims to combine an oncolytic virus platform with JW's approved CD19 CAR-T therapy to target solid tumors.

• Aim to advance a first-in-class "mark and kill" strategy using oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19 CAR-T cells.

• Seek to generate impactful preclinical and clinical data to inform further development of combination immunotherapies.

Partner introductions and roles

• The presenting team includes experienced executives and clinicians with backgrounds in major biotech firms and over 18 FDA-approved drugs.

• Imugene provides the oncolytic virus and leads preclinical work; JW supplies the CAR-T product and sponsors the phase I trial in China.

• One partner provides the oncolytic virus (CF33-CD19/onCARlytics) platform.

• The other partner contributes the CD19 CAR-T cell therapy (Carteyva®) and commercial CAR-T infrastructure.

• Both companies bring expertise in immuno-oncology and cell therapy development.